SCHEMBL4127955

SCHEMBL4127955

CC1CCCN1Cc1ccc(N2CCC3(CC2)CCN(C2CCC2)CC3)cc1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.47
ALDH1A1 P00352 3/20 0.47
L3MBTL3 Q96JM7 5/20 0.46
L3MBTL1 Q9Y468 5/20 0.46
KDM4E B2RXH2 1/20 0.45
PARP1 P09874 1/20 0.41
LTA4H P09960 1/20 0.40
MBTD1 Q05BQ5 1/20 0.39
TP53BP1 Q12888 1/20 0.39
MAPT P10636 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4135288 0.96 ALDH1A1 (0.52) HRH3ALDH1A1L3MBTL3L3MBTL1KDM4E
SCHEMBL4134962 0.85 L3MBTL3 (0.45) HRH3L3MBTL3L3MBTL1LTA4HMBTD1
SCHEMBL4136869 0.83 ALDH1A1 (0.49) HRH3ALDH1A1KDM4EPARP1
SCHEMBL4129322 0.83 HDAC8 (0.49) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4138950 0.83 HDAC8 (0.49) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4137001 0.83 MAPK1 (0.46) HRH3ALDH1A1L3MBTL3L3MBTL1MBTD1
SCHEMBL4131643 0.82 L3MBTL3 (0.56) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4135765 0.81 L3MBTL3 (0.70) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4130764 0.80 L3MBTL3 (0.68) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL4130526 0.80 L3MBTL3 (0.68) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 EP claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US claimed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO claimed
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 EP disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO disclosed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 HRH3 1/4885ALDH1A1 734/4885L3MBTL3 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.